G/P

February 7, 2017February 7, 2017

Hepatitis C Therapy Candidate Granted Priority Review from Health Canada

Hepatitis C, News

A potential new drug being developed for the treatment of chronic hepatitis C received priority review from Health Canada. This means that the compound may be reviewed in advance of ... Read more

January 26, 2017January 26, 2017

Marketing Application for HCV Treatment Candidate G/P Validated in Europe

Hepatitis C, News

AbbVie’s marketing authorization application (MAA) for its investigational drug glecaprevir/pibrentasvir (G/P), developed as a treatment for chronic hepatitis C virus (HCV) genotypes 1 to 6, has been validated by the European ... Read more

November 17, 2016November 17, 2016

AbbVie’s HCV Therapy Looks Highly Effective in Patients with Severe Kidney Disease

Hepatitis C, News

AbbVie recently announced positive results for the company’s investigational regimen of glecaprevir/pibrentasvir (G/P) in treating patients with chronic hepatitis C virus (HCV). Results are from the EXPEDITION-4 study (NCT02651194), an open-label Phase ... Read more